Two delayed-diagnosis case reports of long-lasting thrombocytopenia with splenomegaly

Bing Chen,Wenchu Dai,Yuni Xu,Feng Wang,Jinlin Liu

DOI: https://doi.org/10.1097/md.0000000000039354

IF: 1.6

2024-08-27

Medicine

Abstract:Gaucher disease (GD) is a rare autosomal recessive lysosomal storage disease commonly presenting in pediatric patients with massive splenomegaly. It is caused by mutations in the glucocerebrosidase (GBA) gene that eliminate or significantly reduce the activity of β-glucocerebrosidase (GCase), leading to the accumulation of glucocerebroside in macrophages of several organs, mainly the spleen, liver, and bone marrow. [ 1 ] The global prevalence of GD ranges from 0.39 to 5.80 per 100,000 persons. However, in China, GD is extremely uncommon with a lower incidence rate than the global average. [ 2 , 3 ] GD is classified into 3 types based on clinical manifestations: non-neuronopathic (GD1), acute neuronopathic (GD2), and chronic neuronopathic (GD3). Nearly 95% of GD cases are GD1. [ 4 ] Clinically, patients with GD are often misdiagnosed and may experience significantly delayed diagnosis owing to clinical heterogeneity, including hepatosplenomegaly, cytopenia, delayed growth, abdominal pain, chronic fatigue, and neurological impairments such as cognitive decline. Once GD is suspected, it is confirmed by establishing deficient GCase activity and/or GBA pathogenic genetic testing. [ 5 ] Timely treatment can prevent irreversible damage and improve the quality of life. However, misdiagnosis can lead to disease complications, persistence of untreated symptoms, and depression without an explanation for symptoms. [ 2 , 5 , 6 ] Moreover, the diagnosis and management of patients with chronic multisystem disorders has evolved substantially in recent years. In this report, we present 2 Chinese female patients who presented with long-lasting splenomegaly and thrombocytopenia but who initially refused to undergo further an invasive bone marrow biopsy at a local hospital. However, after admission to our hospital, invasive bone marrow biopsy clearly showed Gaucher-like cells in these 2 patients, leading to a definitive diagnosis of GD. Therefore, we highlight that diagnostic delays in GD cases can occur owing to the refusal of invasive bone marrow biopsies. Although rare, a diagnosis of GD should be considered in every patient with hepatosplenomegaly and thrombocytopenia. In addition, noninvasive GCase activity and GBA gene testing can confirm this rare disease if a patient refuses a bone marrow biopsy. Prompt diagnosis is becoming increasingly important as effective therapies are developed for patients with GD.

medicine, general & internal